238 related articles for article (PubMed ID: 29290695)
1. Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch-Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomenon.
Taha R; El-Haddad H; Almuallim A; Alshaiki F; Obaid E; Almoallim H
Open Access Rheumatol; 2017; 9():201-214. PubMed ID: 29290695
[TBL] [Abstract][Full Text] [Related]
2. B-cell-targeted therapy in systemic vasculitis.
Lally L; Spiera R
Curr Opin Rheumatol; 2016 Jan; 28(1):15-20. PubMed ID: 26599379
[TBL] [Abstract][Full Text] [Related]
3. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?
Kallenberg CG
Curr Opin Rheumatol; 2014 May; 26(3):292-8. PubMed ID: 24646946
[TBL] [Abstract][Full Text] [Related]
4. Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies.
Ayan G; Esatoglu SN; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Fresko I; Ozdogan H; Yurdakul S; Hamuryudan V
Rheumatol Int; 2018 Apr; 38(4):607-622. PubMed ID: 29322343
[TBL] [Abstract][Full Text] [Related]
5. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
Lenert A; Lenert P
Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
[TBL] [Abstract][Full Text] [Related]
6. Impact of rituximab trials on the treatment of ANCA-associated vasculitis.
Alberici F; Jayne DR
Nephrol Dial Transplant; 2014 Jun; 29(6):1151-9. PubMed ID: 24126571
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
8. Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?
Tesar V; Hruskova Z
Expert Opin Pharmacother; 2015; 16(11):1683-702. PubMed ID: 26149512
[TBL] [Abstract][Full Text] [Related]
9. Biologics for childhood systemic vasculitis.
Akamine K; Punaro M
Pediatr Nephrol; 2019 Nov; 34(11):2295-2309. PubMed ID: 30203375
[TBL] [Abstract][Full Text] [Related]
10. Rituximab treatment for IgA vasculitis: A systematic review.
Hernández-Rodríguez J; Carbonell C; Mirón-Canelo JA; Diez-Ruiz S; Marcos M; Chamorro AJ
Autoimmun Rev; 2020 Apr; 19(4):102490. PubMed ID: 32062030
[TBL] [Abstract][Full Text] [Related]
11. B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis.
Kallenberg CG; Hauser T
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i119-22. PubMed ID: 25753806
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
[TBL] [Abstract][Full Text] [Related]
14. Brief Report: Rituximab for the Treatment of Adult-Onset IgA Vasculitis (Henoch-Schönlein).
Maritati F; Fenoglio R; Pillebout E; Emmi G; Urban ML; Rocco R; Nicastro M; Incerti M; Goldoni M; Trivioli G; Silvestri E; Mohammad AJ; Jayne D; Eriksson P; Segelmark M; Novikov P; Harris H; Roccatello D; Vaglio A
Arthritis Rheumatol; 2018 Jan; 70(1):109-114. PubMed ID: 28973844
[TBL] [Abstract][Full Text] [Related]
15. Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives.
Treppo E; Binutti M; Agarinis R; De Vita S; Quartuccio L
J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501224
[TBL] [Abstract][Full Text] [Related]
16. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
[TBL] [Abstract][Full Text] [Related]
17. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
19. Remission Induction Therapy with Rituximab for Microscopic Polyangiitis: A Feasibility Study.
Saito A; Takeuchi Y; Kagaya S; Ojima Y; Fukami H; Sato H; Matsuda K; Nagasawa T
Tohoku J Exp Med; 2017 May; 242(1):53-62. PubMed ID: 28539536
[TBL] [Abstract][Full Text] [Related]
20. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.
Wendt M; Gunnarsson I; Bratt J; Bruchfeld A
Scand J Rheumatol; 2012 Mar; 41(2):116-9. PubMed ID: 22118245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
